Halbesma Nynke, Kuiken Dirk-Sjoerd, Brantsma Auke H, Bakker Stephan J L, Wetzels Jack F M, De Zeeuw Dick, De Jong Paul E, Gansevoort Ronald T
Division of Nephrology, Department of Medicine, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands.
J Am Soc Nephrol. 2006 Sep;17(9):2582-90. doi: 10.1681/ASN.2005121352. Epub 2006 Aug 9.
Macroalbuminuria, erythrocyturia, and impaired renal function are strong predictors of poor renal outcome in patients with known renal disease. However, the yield of mass screening for these variables to identify individuals who are at risk for GFR loss is yet unknown in a Western population. With the use of data from the Prevention of Renal and Vascular End-Stage Disease (PREVEND) study, a prospective, population-based cohort study, the cardiovascular and renal prognosis was investigated in patients with classical renal risk markers: Macroalbuminuria (> or =300 mg albumin/24 h urine), erythrocyturia (> or =250 erythrocytes/L, without leukocyturia), and impaired renal function (both 24-h creatinine clearance and Modification of Diet in Renal Disease clearance below the fifth percentile of age- and gender-matched control subjects). The 8592 patients who were included in this study were followed for a 4-yr period. We identified 134 patients with macroalbuminuria, 128 with erythrocyturia, and 103 with impaired renal function. There was only a little overlap among the three groups. The prevalence of macroalbuminuria, erythrocyturia, and impaired renal function was calculated to be in the general population 0.6, 1.3, and 0.9%, respectively. In all three groups, fewer than 30% of patients were known to have this laboratory abnormality before screening. The incidence of cardiovascular disease was high in the macroalbuminuria group (e.g., the age- and gender-adjusted hazard ratio for mortality as a result of cardiovascular disease is 2.6 [1.1 to 6.0]) and for the impaired renal function group (3.4 [1.5 to 8.0]). After a mean follow-up of 4.2 yr, the macroalbuminuria group showed a -7.2 ml/min per 1.73 m2 estimated GFR (eGFR) loss, compared with -2.3 ml/min per 1.73 m2 in the control group (difference P < 0.001), whereas the rate of eGFR loss in the impaired renal function group (-0.2 ml/min per 1.73 m2; P = 0.18) and the erythrocyturia group (-2.6 ml/min per 1.73 m2) was not different from the control group. Macroalbuminuria and impaired renal function both predict a worse prognosis with respect to cardiovascular morbidity and mortality. However, macroalbuminuria is a better risk marker than low eGFR or erythrocyturia to identify in population screening of individuals who are at risk for accelerated GFR loss.
大量蛋白尿、红细胞尿和肾功能受损是已知肾病患者肾脏预后不良的有力预测指标。然而,在西方人群中,通过对这些变量进行大规模筛查以识别有肾小球滤过率(GFR)下降风险个体的收益尚不清楚。利用预防肾脏和血管终末期疾病(PREVEND)研究的数据,一项前瞻性、基于人群的队列研究,对具有经典肾脏风险标志物的患者的心血管和肾脏预后进行了调查:大量蛋白尿(≥300mg白蛋白/24小时尿)、红细胞尿(≥250个红细胞/升,无白细胞尿)和肾功能受损(24小时肌酐清除率和肾脏病饮食改良公式计算的清除率均低于年龄和性别匹配对照组的第五百分位数)。本研究纳入的8592例患者随访了4年。我们确定了134例大量蛋白尿患者、128例红细胞尿患者和103例肾功能受损患者。三组之间仅有少量重叠。计算得出大量蛋白尿、红细胞尿和肾功能受损在普通人群中的患病率分别为0.6%、1.3%和0.9%。在所有三组中,筛查前已知有这种实验室异常的患者不到30%。大量蛋白尿组心血管疾病的发生率较高(例如,因心血管疾病导致死亡的年龄和性别调整后的风险比为2.6[1.1至6.0]),肾功能受损组也是如此(3.4[1.5至8.0])。在平均随访4.2年后,大量蛋白尿组的估计GFR(eGFR)下降为每1.73m² -7.2ml/min,而对照组为每1.73m² -2.3ml/min(差异P<0.001),而肾功能受损组(每1.73m² -0.2ml/min;P = 0.18)和红细胞尿组(每1.73m² -2.6ml/min)的eGFR下降率与对照组无差异。大量蛋白尿和肾功能受损均预示着心血管发病率和死亡率方面更差的预后。然而,在人群筛查中,大量蛋白尿比低eGFR或红细胞尿是更好的风险标志物,可用于识别有加速GFR下降风险的个体。